The Weekly Recap 7/17/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni launch new partnerships, receive new funding, appoint new executives, and much more on the road to LSI Europe ‘26 in Barcelona (September 28 - October 1).

AccurKardia & Wellysis

Signed a multi-year agreement under which AccurKardia’s AccurECG 2.0 will power the analytics behind Wellysis’ turnkey cardiac monitoring offering in the U.S. Under the agreement, Wellysis’ S-Patch wearable device will be paired with AccurKardia’s automated ECG analytics and reporting platform to deliver a complete, clinician-ready solution for Holter, extended Holter, and mobile cardiac telemetry workflows.

Amsel Medical

Announced positive final results from its GLP animal study evaluating the SCureTVOC™ Temporary Vascular Occlusion Clamp, successfully meeting all safety, usability, vessel occlusion, patency, and pathological study endpoints. The ultrasound-guided device is designed to temporarily control hemorrhage in traumatic injuries, including areas where tourniquets cannot be applied, while maintaining blood flow until definitive vascular repair is completed.

Angela Paterson

Launched Evolution Medtech, a boutique consultancy dedicated to partnering with medical device startups and innovators. The team brings decades of experience in medical devices across regulatory affairs, quality management, clinical strategy, and medical affairs.

AtaCor Medical

Enrolled the first patient in its ALARION-EV study. The trial evaluates an investigational next-generation parasternal extravascular implantable cardioverter-defibrillator (EV-ICD) system featuring AtaCor's Atala™ lead in combination with an EV-ICD pulse generator developed by Abbott in patients who are indicated for a standard ICD but do not require chronic pacing therapy for slow heart rhythms.

Glucotrack

Completed its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed, capital-efficient platform for the identification, acquisition, and advancement of differentiated healthcare assets. The transaction is structured such that Lōkahi Therapeutics becomes the operating and controlling business of the combined company, leveraging the company’s public market platform to support long-term growth and access to capital.

Histosonics

Received CE Mark approval in Europe for its Edison^® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. The Edison System is a novel, non-invasive, image-guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors.

illumicell AI

Welcomed LSI Alumni Trevor Slattery as its CTO, a tech executive operating at the intersection of AI and cybersecurity, with deep domain expertise in regulated medical technology. The company also welcomed Ken Johnson as its Head of Software Development, a software engineering expert working at the intersection of medical imaging, computer vision, physics-based signal processing, and FDA-regulated product development.

Nervonik

Expanded its leadership team with the appointments of Rob DiTota as Chief Commercial Officer, Dan Brounstein as Chief Strategy and Marketing Officer, and Patrick Martin as Vice President of Clinical Affairs. The three executives bring decades of experience in neuromodulation, medical device commercialization, clinical affairs, and strategy to support the company’s planned FDA 510(k) submission and commercial launch.

Newronika

Received CE Mark certification for the latest commercial release of αDBS^®, its adaptive deep brain stimulation system, now including full integration with WebBioBank™, its proprietary cloud-based neural data platform. Powered by a patented Adaptive Therapy Stim Engine, αDBS continuously senses local field potential (LFPs), reading the brain's signals in real time and adjusting the stimulation to keep each patient within their optimal therapeutic window.

Nyra Medical

Enrolled the first patient in the ENHANCE Early Feasibility Study evaluating the investigational CARLEN™ System. The device is designed to restore native mitral valve leaflet coaptation without sutures, tethers, or permanent anatomical changes while preserving physiologic leaflet motion and future treatment options.

OncoRes Medical

Received a $3M Cooperative Research Centres Projects (CRC-P) grant from the Australian Government to accelerate the development of technologies aimed at improving the precision of prostate cancer surgery and patient outcomes. The three-year collaborative project with The University of Western Australia and Clinipath Pathology will advance Quantitative Micro Elastography (QME) technology through benchtop, biopsy, and first-in-human studies.

PDV MedTech

Announced a strategic partnership with Corscience to give medtech innovators an end-to-end path from early-stage development to manufacturing and commercialization. The alliance combines Corscience’s deep engineering expertise in complex medical devices with PDV MedTech’s U.S. and global manufacturing infrastructure, aiming to reduce friction, shorten timelines, and expand access to specialized capabilities across Europe and the U.S.

Rx Bandz

Received additional funding from Leonid Capital Partners, bringing the firm’s total financing in the company to over $6.5M. The company plans to use the proceeds to continue developing therapeutics focused on battlefield pain management and FDA submission.

Solaris Endovascular

Received an additional investment from UT Ventures, contributing to the company’s oversubscribed $5M convertible bridge round. The company’s lead product, Solaris DE, is a sirolimus-eluting covered stent designed to address restenosis and improve long-term durability in dialysis access, with potential applications across a broader range of vascular conditions.

THINK Surgical

Entered into a debt facility with Symbiotic Capital, which will provide up to $65M of growth capital. The company plans to use the proceeds to continue advancing its dual-channel commercial strategy for its TMINI^® Miniature Robotic System, which is currently compatible with approximately 70% of the market share for total knee implants.

ViCentra (Kaleido)

Appointed Ian Wells as CFO and welcomed LSI Alumni Thomas A. West, a veteran U.S. medical technology leader, to its Board of Directors as an Independent Director. The appointments lay the financial and governance foundation for the company to scale across Europe and enter the U.S. market following a year of sustained operational momentum.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.